Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Moody's Corporation (MCO) Price & Performance

Cassava Sciences IncTrade
Moody's CorporationTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Moody's Corporation — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Moody's Corporation trades at $477.55 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 1728.2× Cassava Sciences Inc's market cap, and Moody's Corporation pays a 0.86% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAMCO
Market Cap
$47.75M$82.52B
Sector
HealthFinancials
52-Week High
$4.64$539.61
52-Week Low
$0.87$412.23
Enterprise Value
-$34.93M$88.54B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Moody's Corporation

Moody's Corporation (MCO) trades at $478.14, showing modest daily gains of 0.08%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust profitability metrics, including 34.25% net income margin and 80.15% ROE. Recent Q2 2026 results exceeded expectations with $4.68 EPS versus $4.26 expected, driven by strong analytics demand and debt issuance activity. Technical indicators remain neutral with support at $475 and resistance at $481.

MCO presents a compelling growth story with premium valuation justified by exceptional profitability and market leadership. The primary investment opportunity lies in sustained analytics growth and credit rating dominance, while risks include valuation sensitivity and potential debt market volatility. Analyst consensus remains bullish with $561.88 price target representing 17.5% upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

Read more on MCO